文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

标准化口腔护理包中加入氯己定预防呼吸机相关性肺炎:六所内科ICU的实用整群随机交叉试验

Chlorhexidine within a standardized oral-care bundle for the prevention of ventilator-associated pneumonia: a pragmatic cluster-randomized crossover trial in six medical intensive care units.
PubMed 文献 · Crit Care · 2026-10-29
一句话结论在混合内科ICU中,标准化口腔护理包加入0.12%氯己定未降低VAP发生率或28天死亡率,且与ICU住院时间轻度延长相关。

该研究为在印度单一三级学术医院六所成人内科ICU开展的前瞻性实用整群随机交叉试验,纳入机械通气≥48小时的连续成人患者。ICU随机分为使用不含氯己定的多成分口腔护理包或相同护理包加0.12%氯己定,共纳入1035例患者(无氯己定组637例,氯己定组398例),累计10024个呼吸机日。主要终点VAP发生率密度(CPIS>6)在无氯己定组为16.9/1000呼吸机日,氯己定组为18.8/1000呼吸机日,调整后Poisson发生率比为1.08(95%CI 0.84-1.38;p=0.56)。28天死亡率28.7% vs 26.4%(调整OR 0.87,95%CI 0.65-1.15;p=0.33),氯己定组ICU住院时间延长(调整平均差+0.89天,95%CI +0.19至+1.58;p=0.013)。结论认为在混合内科ICU常规使用氯己定无明确增量获益。

要点

  • 在六所内科ICU的机械通气≥48小时成人中,标准化口腔护理包加0.12%氯己定未降低VAP发生率密度(调整IRR 1.08,95%CI 0.84-1.38;p=0.56)。
  • 氯己定组28天死亡率与无氯己定组无显著差异(26.4% vs 28.7%;调整OR 0.87,95%CI 0.65-1.15;p=0.33)。
  • 氯己定组ICU住院时间较无氯己定组轻度延长(调整平均差+0.89天,95%CI +0.19至+1.58;p=0.013)。
  • BOAS和CPOT评分在两组间无差异,提示口腔评估与疼痛评分未因氯己定而改善。
  • 该试验为实用整群随机交叉设计,结果不支持在混合内科ICU常规将0.12%氯己定加入标准化口腔护理包以预防VAP。

适用人群与场景

  • 纳入:六所成人内科ICU中连续机械通气≥48小时的成人患者。
  • 排除:原文未提及具体排除标准。
  • 场景:单一三级学术医院的内科ICU,非心脏外科ICU。

诊断标准与关键阈值

  • VAP诊断标准:临床肺部感染评分(CPIS)>6。
  • 主要终点:VAP发生率密度,按每1000个呼吸机日计算。

处置流程与药物剂量

  • 干预:标准化多成分口腔护理包,或相同护理包加0.12%氯己定;具体给药途径、频次和疗程原文未提及。
  • 对照:不含氯己定的标准化多成分口腔护理包;具体成分原文未提及。
  • 原文未提及氯己定的具体剂量(每次用量)、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性、实用整群随机交叉(AB/BA)试验,六所成人内科ICU,单中心。
  • 样本量:1035例患者(无氯己定组637例,氯己定组398例),累计10024个呼吸机日(5918 vs 4106)。
  • 主要终点:VAP发生率密度无氯己定组16.9/1000呼吸机日 vs 氯己定组18.8/1000呼吸机日;调整Poisson发生率比1.08(95%CI 0.84-1.38;p=0.56)。
  • 关键次要终点:28天死亡率28.7% vs 26.4%(调整OR 0.87,95%CI 0.65-1.15;p=0.33);ICU住院时间氯己定组延长(调整平均差+0.89天,95%CI +0.19至+1.58;p=0.013);BOAS和CPOT评分无差异。
  • 不良事件:原文未提及具体不良事件。

证据类型、等级与局限

  • 证据类型:前瞻性实用整群随机交叉试验。
  • 局限:单中心、整群随机设计、样本量有限(氯己定组398例),原文未报告盲法及具体不良事件。

对床旁实践的改变

  • 在混合内科ICU机械通气≥48小时成人中,不应常规在标准化口腔护理包中加入0.12%氯己定以预防VAP,因无增量获益且与ICU住院时间轻度延长相关。
  • 该结论不适用于心脏外科ICU或其他人群,原文未提供相关数据。
  • 临床陷阱:不能将本试验结果外推为氯己定有害;原文仅显示无明确增量获益。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Chlorhexidine (CHX) has been a long-standing component of oral-care bundles for preventing ventilator-associated pneumonia (VAP), but recent evidence has questioned its benefit in non-cardiac-surgery ICU. We evaluated whether adding 0.12% CHX to standardized oral-care bundle provides incremental benefit in a mixed medical ICU.

METHODS: We conducted a prospective, pragmatic cluster-randomized crossover (AB/BA) trial in six adult medical ICUs of a single tertiary-care academic hospital in Bhubaneswar, India. ICUs were randomized as three ICUs of two Period of 9 months with the multicomponent oral-care bundle without chlorhexidine and three with the same bundle plus 0.12% chlorhexidine with a 1-month wash-in and re-training interval. Consecutive adults ventilated for ≥ 48 h were included. The primary outcome was VAP incidence density (Clinical Pulmonary Infection Score (CPIS) > 6) as per 1,000 ventilator-days. Secondary outcomes were 28-day all-cause mortality, duration of mechanical ventilation, ICU length of stay, 28- day ventilator-free days, Beck Oral Assessment Scale (BOAS) and Critical-Care Pain Observation Tool (CPOT) scores. The primary model was a population-averaged Poisson generalized estimating equation (GEE) and adjustment for treatment, period, sequence, age, sex, APACHE II, and SOFA.

RESULTS: A total of 1,035 patients (637 No CHX, 398 CHX) accrued 10,024 ventilator-days (5,918 vs. 4,106). Groups were well balanced at baseline (mean age ≈ 55 years; APACHE II ≈ 19.6; SOFA ≈ 13.4). VAP occurred in 100/5,918 ventilator-days (16.9 per 1,000) vs. 77/4,106 (18.8 per 1,000) (No CHX vs. CHX). The adjusted Poisson incidence rate ratio was 1.08 (95% CI 0.84-1.38; p = 0.56). 28-day mortality was 28.7% vs. 26.4% (no CHX vs. CHX) (adjusted OR 0.87, 95% CI 0.65-1.15; p = 0.33). ICU length of stay was longer in the CHX arm (adjusted mean difference + 0.89 days, 95% CI + 0.19 to + 1.58; p = 0.013). BOAS and CPOT scores did not differ.

CONCLUSIONS: In this trial, adding 0.12% chlorhexidine to a standardized oral-care bundle did not reduce VAP incidence density or 28-day mortality and was associated with a modest increase in ICU length of stay. Routine CHX use provided no clear incremental benefit in a mixed medical ICU population.

TRIAL REGISTRATION: Clinical Trials Regisrty- India (CTRI) identifier [CTRI/2024/02/062201], registered [01 February 2024].

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Anushapreethi S, Chhotray P, Samal S, et al. Chlorhexidine within a standardized oral-care bundle for the prevention of ventilator-associated pneumonia: a pragmatic cluster-randomized crossover trial in six medical intensive care units. Crit Care. 2026. PMID: 42958418. doi:10.1186/s13054-026-06217-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。